3',3'''-biapigenin

3',3'''-Biapigenin is a natural product for research related to life sciences. The catalog number is TN5500 and the CAS number is 151455-26-4.

2'',3''-Dihydro-3',3'''-biapigenin is a natural product for research related to life sciences. The catalog number is TN5496 and the CAS number is 151455-25-3.

3,8''-Biapigenin (Standard) is a reference standard for research and analysis in studies involving 3,8''-Biapigenin. 3, 8''-Biapigenin can modulate intracellular ROS production.

3, 8''-Biapigenin can modulate intracellular ROS production.

Amentoflavone (3',8''-Biapigenin), as a potent inhibitor of CYP3A4 and CYP2C9, can interact with many other medications. CYP3A4 and CYP2C9 are proteins used for drug metabolism in the body. Amentoflavone also is an inhibitor of human cathepsin B. It has antimalarial activity in trials significant affinities towards the Delta-1, kappa opioid receptors (as an antagonist) and binds to benzodiazepine receptors. Amentoflavone may be a potential lead for a new type of anti-inflammatory agents having the dual inhibitory activity of group II phospholipase A2 and cyclooxygenase. Amentoflavone and quercetin differentially exerted suppression of PGE2 biosynthesis via downregulation of COX-2/iNOS expression.

Amentoflavone (Standard) is a reference standard for research and analysis in studies involving Amentoflavone. Amentoflavone (3',8''-Biapigenin), as a potent inhibitor of CYP3A4 and CYP2C9, can interact with many other medications. CYP3A4 and CYP2C9 are proteins used for drug metabolism in the body. Amentoflavone also is an inhibitor of human cathepsin B. It has antimalarial activity in trials significant affinities towards the Delta-1, kappa opioid receptors (as an antagonist) and binds to benzodiazepine receptors. Amentoflavone may be a potential lead for a new type of anti-inflammatory agents having the dual inhibitory activity of group II phospholipase A2 and cyclooxygenase. Amentoflavone and quercetin differentially exerted suppression of PGE2 biosynthesis via downregulation of COX-2/iNOS expression.